Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients with Acute Optic Neuritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jan 2026 According to an Oculis Pharma media release, Privosegtor is granted Breakthrough Therapy Designation by the USFDA supported by visual-function results from the Phase 2 ACUITY trial in optic neuritis (ON).
22 Sep 2025 Results presented in an Oculis Pharma media release
22 Sep 2025 According to an Oculis Pharma media release, data from this trial to be presented in upcoming presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress, Thursday, September 25, 2025; 16:30 CET

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com